Evaluation of oral fluid enzyme immunoassay for confirmation of a positive rapid human immunodeficiency virus test result

Clinical and Vaccine Immunology

Volumn 16, Issue 7, 2009, Pages 1091-1092

  Wesolowski, L G ^a,c   Sanchez, T ^a   MacKellar, D A ^a   Branson, B M ^a   Ethridge, S F ^a   Constantine, N ^b   Ketema, F ^b   Sullivan, P S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ENZYME IMMUNOASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE TEST; PERFORMANCE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SALIVA ANALYSIS; WESTERN BLOTTING;

HIV; HIV INFECTIONS; HUMANS; IMMUNOENZYME TECHNIQUES; MOUTH;

EID: 67650364755     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00083-09     Document Type: Article

References (4)

1. bioMérieux. 19 December 2006. bioMérieux to phase out microplate immunoassay production in the United States. bioMérieux, Marcy-l'Etoile, France. http://www.biomerieux-usa.com/news/pressreleases/ microplate-pressrelease.htm.
2. Centers for Disease Control and Prevention. 2004. Protocols for confirmation of reactive rapid HIV tests. MMWR Morb. Mortal. Wkly. Rep. 53:221-222.
3. Centers for Disease Control and Prevention. 2007. Quality assurance guidelines for testing using rapid HIV antibody tests waived under the Clinical Laboratory Improvement Amendments of 1988. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA. http://www.cdc.gov/hiv/topics/testing/resources/guidelines/qa-guide.htm.
4. Coates, R., M. Millson, T. Myers, et al. 1991. The benefits of HIV antibody testing of saliva in field research. Can. J. Public Health. 82:397-398.